News BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
2.59 ^USD	-3.36%		-1.52%	-12.20%

Apr. 10	Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	CI
Mar. 25	BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia	Apr. 10	AQ
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	Apr. 10	CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	Mar. 25	MT
BioXcel Therapeutics Announces $25 Million Registered Direct Offering	Mar. 25	AQ
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	Mar. 15	MT
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine	Mar. 15	AQ
Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating	Mar. 14	MT
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating	Mar. 13	MT
Transcript : BioXcel Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 12	CI
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023	Mar. 12	AQ
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024	Mar. 01	AQ
North American Morning Briefing : Nvidia Ignites -2-	Feb. 22	DJ
UBS Downgrades BioXcel Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $9	Feb. 21	MT
BioXcel Therapeutics Shares Soar After Terminating Proposed $60 Million Stock Offering	Feb. 13	MT
BioXcel Therapeutics Announces Termination of Proposed Public Offering	Feb. 13	AQ
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer	Feb. 12	MT
BioXcel Therapeutics, Inc. Enter into the Third Amendment to Credit Agreement and Guaranty	Feb. 12	CI
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation	Feb. 12	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Summary

Filters